banner





frame bio
bio
bio
bio


Biomarkers


In using proteomic analyses of synovial fluid, skin and blood samples of patients with psoriatic disease, we have identified a number of proteins that are markers for psoriatic arthritis or can distinguish psoriatic arthritis patients from patients with psoriasis. For example, CD5L, ITGbeta5, M2BP, MPO, MMP-3, and CRP level are markers for PsA. The combination of ITGbeta5, M2BP, and CRP level differentiates PsA from PsC, and performs better than CRP level alone. The ultimate goal of our biomarker studies is the improved and personalized management of psoriatic disease by:
1. Aiming at early diagnosis of PsA;
2. Identifying patients with psoriasis at high risk of developing arthritis and developing interventions to intercept this transition;
3. Identifying subjects with PsA at high risk of developing arthritis mutilans, a severe form of psoriatic arthritis.



Omics


In using proteomic analyses of synovial fluid, skin and blood samples of patients with psoriatic disease, we have identified a number of proteins that are markers for psoriatic arthritis or distinguished between PsA and PsC. For example, CD5L, ITGbeta5, M2BP, MPO, MMP-3, and CRP level are markers for PsA. The combination of ITGbeta5, M2BP, and CRP level differentiates PsA from PsC, and performs better than CRP level alone.

The proteomics efforts are coupled by microbiomic investigations. By exploring the microbiome of skin, intestinal and synovial fluid of patients with psoriasis and psoriatic arthritis in the context of the patient's clinical information, we study the possible role of bacteria in the pathogenesis of psoriatic disease and the exploration of the host-microbial networks for the identification of novel drug targets. Our current investigation of stool microbiome also has also the potential to provide new insights about PsA.

Our more recent investigations expanded on studying the metabolite profile of psoriatic disease in order to identify metabolomic markers for diagnosis, stratification, and treatment response. Our laboratory is affiliated with the Metabolomics Core Facility of the Schroeder Arthritis Institute.

We also apply computational, statistical, and big data visualization techniques to predict activity context of protein interactions and study network rewiring in psoriatic arthritis. As part of this work, we integrate multiple omics data, and utilize machine algorithms, artificial intelligence, and statistics to better elucidate the cellular networks involved in disease pathogenesis.



Functional studies


We are currently looking at protein and peptide expression in the synovial fluid and investigating the proteolytically-regulated receptor activation in synovial fluid and blood-derived cells of patients with psoriatic arthritis and other inflammatory arthritides. Activity of proteinases known to be expressed in the synovial fluid, serine, cysteine and metallo-proteinases, and their proteinase receptors, with a focus on proteinase-activated receptor 2, are evaluated. Key immune cells and involved signaling pathways related to inflammation and pain are further functionally investigated.



Drug discovery


With a focus to evaluate our biomarker and functional findings as potential drug targets we have been using cell culture and tissue explant models reminiscent of psoriatic disease, to screen for potential therapeutic compounds. We have recently recruited augmented intelligence tools to help us accelerate these efforts. Our ultimate goal is to develop drug or other interventions to treat the estimated 40% of psoriatic arthritis patients not responding to current therapy.



Psoriatic Arthritis Research Program


Dr. Chandran serves as the co-director of the Psoriatic Arthritis Research Program at Toronto Western Hospital. The work of the PsA research program focuses on: genetics, transcriptomics, epigenomics and microRNA analyses of samples from PsD patients.
https://www.torontopsdprogram.com/









Department of Rheumatology
University Health Network
Contact information